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The six divisions of the Cooperative Human Tissue Network in the USA bank and distribute tens of thousands of tissue specimens to
researchers annually. Major operational concerns include: maintaining tissue integrity, managing informatics, and protecting patient
confidentiality. Increasing molecular genetics testing is also resulting in an increased demand for high-quality nucleic acids.
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This review will deal with the broad concepts of tumour banking
and informatics as practiced at the Biopathology Centers (BPC)
located at the Children’s Research Institute, Columbus, Ohio, USA.
The BPC provides banking and informatics services to a variety of
cancer cooperative groups under the tutelage of the Cooperative
Human Tissue Network, including: Children’s Oncology Group
(COG), Gynecologic Oncology Group (GOG), and Childhood
Cancer Survivor Study (CCSS). The BPC deals with patient
specimens that span the age range of newborns to the elderly;
procuring tumour types that include the spectrum of paediatric
solid tumours, selected adult gynaecologic tumours (ovarian,
cervical, uterine), and any second malignant (solid) neoplasm in
childhood cancer survivors. In the last decade, the BPC has served
nearly 85000 tumour or related tissue specimens to over 300
different investigators. These specimens are linked to patient
clinical outcome, because of the BPC’s alliance with the
aforementioned cooperative groups.
T h eN a t i o n a lC a n c e rI n s t i t u t eC o o p e r a t i v eH u m a nT i s s u eN e t w o r k
(CHTN) itself was founded 15 years ago ‘to stimulate, for the good of
the public, cooperative efforts to collect and distribute human tissues
and to thereby facilitate research utilising those tissues’. These
activities are expected to encourage basic, developmental, and
translational studies in many areas of cancer research including
molecular biology, immunology, and genetics. The six institutions
comprising the CHTN currently include the University of Pennsylva-
nia (V LiVolsi, PI), University of Alabama at Birmingham (W Grizzle,
PI), The Ohio State University (N Ramirez, PI), Columbus Children’s
Hospital (S Qualman, PI), The University of Virginia (C Moskaluk,
PI) and Vanderbilt University (M Washington, PI). The CHTN does
not provide fresh or frozen tissues with known pathogens or foetal
tissues for research purposes. Collectively, these institutions supply
an estimated 80000 research specimens to hundreds of investigators
annually. The CHTN as a whole is devoted primarily to the
prospective procurement of tissue for immediate disbursal to
investigators, rather than banking of specimens, but many of the
logistical, informatic, and ethical issues are the same.
BANKING
Many of the details of banking and informatics discussed below can
be found in a recently published book chapter (Qualman et al, 2003),
which ties these needs to the advancement of molecular research.
The design of tumour banks should be such that significant
effort is devoted to obtaining data on clinical outcomes (Grizzle
and Sexton, 1999), which permits investigators to know that such
data are available for analysis as they pursue their molecular
studies on bank-derived specimens. Tumour banking and its
associated inventory informatics have been recognised for over a
decade (Naber et al, 1992; Naber, 1996) as needed tools to advance
the science of molecular testing; however, it has only been in the
last 2–3 years that the linkage to clinical outcomes has been seen
as crucial to achieving this goal (Naber et al, 1992). It is estimated
that by the year 2005 (Farkas et al, 1996), as much as 10% of
clinical laboratory tests will be based on RNA or DNA analysis.
These efforts (Abati and Liotta, 1996) will only be successful with
the logical application of tumour banking and its associated
informatics systems as the translational bridge linking new
molecular information to its clinical significance.
Specimen transport
Cooperative group affiliated institutions must send specimens to
the BPC through air-express couriers within 24h of procurement,
using dual-chamber kits, which allow for simultaneous delivery of
specimens at ambient and deep-frozen temperatures (Qualman
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www.bjcancer.comet al, 2003). In those situations, the BPC provides institutions with
a courier account number to encourage rapid shipment. Shipments
made via overnight carrier must be packaged to conform with
International Air Transport Association (IATA) Section 1.5.0.2
(http://www.iata.org/index.htm). Researchers receiving specimens
are billed for shipping charges and an additional specimen-
processing fee associated with the types and numbers of specimens
served. A toll-free telephone number is maintained for contacts
with both institutions submitting specimens and investigators.
Storage facility
Most tissues at the BPC are stored in liquid nitrogen vapour-phase
freezers, because specimens kept at approximately 1701C are of
higher integrity than those maintained at higher temperatures and
show less desiccation (Grizzle et al, 1998; Grizzle and Sexton,
1999). Freezers (801C) are used for short-term tissue storage (1
week or less) and storage of blood and serum whereas 201C
freezers are used for reagent storage. Manual defrost units are
preferred as the freeze–thaw cycles of automatic defrost units can
degrade the quality of biologics and reagents.
Paraffin blocks, scrolls, and slides are best preserved in vacuum-
sealed mylar bags with a commercial oxygen absorber at 41C.
Paraffin slides may also be dipped in molten paraffin prior to
storage to preserve tissue antigenicity (Camp et al, 2000). The BPC
utilises a cold room (walk-in cooler) (41C) for storing its vacuum-
sealed unstained slides and paraffin blocks.
Touch preparations, taken and fixed from fresh tumour
specimens, were once standard submissions to the BPC, but are
now best performed from segments of snap-frozen tissue stored at
the bank. These can then be fixed and sent to the investigator with
relatively good preservation of antigenicity and morphology.
Long-term storage (more than 1 week) of specimens in vapour-
phase liquid nitrogen freezers is done in small segments (e.g. 5g or
less) in plastic histology cassettes or mega-cassettes with the
specimens wrapped in aluminium foil to minimise desiccation.
OCT-embedded specimens in cryomoulds should likewise be
wrapped in foil. Glass vials and pop-top plastic vials are not
adequate storage containers for vapour-phase liquid nitrogen
temperatures, as they may readily break or pop open (Grizzle and
Sexton, 1999). Screw-cap cryovials work well for storage of serum
or urine.
Quality assessments
Central morphologic reviews are performed on the formalin-fixed
tissues sent via the dual-chamber kits which represent the mirror-
image of samples of snap-frozen tumour and normal adjacent
tissue also included in the kit. The histologic analyses include such
parameters as: assessment of tumour diagnosis, percent tumour,
percent stroma, and percent necrosis.
In a BPC sample of 7000 paediatric and gynaecologic tumours
examined over a 5-year period, a diagnostic discrepancy rate of
approximately 10% between central and institutional diagnoses
was identified. Although this discrepancy rate might at first appear
to be quite high, these data in the main reflect sampling problems
identified in tissue aliquots labelled by the submitting institution
as ‘normal’ or ‘tumour’ which were not reflective of the aliquot’s
content (e.g. tissue totally necrotic, normal tissue contaminated by
tumour, etc.). Less than 2% of cases contained true discrepancies
between central review and institutional diagnoses – most of which
were minor, reflecting differing opinions as to tumour grade or
subtype.
A larger analysis of frozen paediatric specimens from 17500
cases banked between 1993 and 2003 showed only 0.4% (70 of
17500 cases) had ‘problems’ with tumour content. Of these, 43%
were deemed to have insufficient tumour, 30% had no tumour and
19% did not have viable tumour. The remaining 8% of cases were
for problematic for miscellaneous reasons.
The 10% diagnostic discrepancy rate quoted above does
emphasise the need for morphologic review of submitted tissues
so that extremely necrotic or contaminated tissue aliquots
(‘normal’ with tumour) are not served to investigators. The central
review diagnosis is used as the standard in serving investigators.
Confirmation of morphologic viability of tissues is only the first
step in assessing the quality of tissues served to investigators. With
an increasing emphasis on molecular uses of BPC tissues, efforts to
assess the molecular integrity of tissue became necessary. The
CHTN has looked at the molecular integrity of its gynaecologic
specimens by RT–PCR and DNA and ribosomal RNA electro-
phoresis performed on ovarian tissue samples (Jewell et al, 2002).
RT–PCR assay for amplification of the mRNA gene product
(177bp product) of the HPRT housekeeping gene revealed
adequate amplification in 70% of ovarian cases. RNA electrophor-
esis (assessed by visual estimate of the 18s and 28s ribosomal RNA
bands by ethidium bromide staining) also revealed RNA to be of
good quality with minimal degradation in 70% of ovarian tissues.
DNA electrophoresis showed the genomic DNA was of good
quality in 100% of ovarian tissues tested. A collection of solid
paediatric tumours collected between 2001 and 2003 was also
analysed by RT–PCR. Only four out of these 95 cases (4.2%) were
deemed to have insufficient or degraded RNA.
Given limitations on amounts of available tissue, preservation
on-site of mRNA by timely snap-freezing of tissues in liquid
nitrogen becomes paramount. BPC personnel annually train
cooperative group personnel at their meetings in the timely
freezing of such tissues. Review of quality control data from the
BPC database allows for verification of improved institutional
performance in this task. The BPC does this by eliciting feedback
from investigators on the quality of their tissues (RNA/DNA
‘preservation’) annually. These data are matched to the institu-
tional tissue source, to give institutional feedback on their
performance in tissue procurement.
Unfortunately, time and expense limit the extent of molecular
surveillance. A limited number of extractions are currently
performed on-site for select cancer specimens. DNA quality is
measured by PCR amplification of an approximately 950bp
fragment whereas RNA integrity is measured by either RT–PCR
or an Agilent 2100 bioanalyzer (Palo AHCA). The Agilent 2100
bioanalyzer uses a disposable RNA chip to determine the
concentration and purity/integrity of 12 RNA samples at a time
(using as little as 50ng each) with a total throughput of 25min. The
system permits rapid screening of a RNA preparation for sample
degradation and ribosomal RNA contamination.
The BPC is developing a core facility for extracting nucleic acids
from a larger number of tissues which will not only provide more
molecular quality control data, but centralised extraction should
also allow more investigators to be served per unit of tissue. Our
experience has been that we can obtain approximately 1–10mgo f
RNA per milligram of viable tissue, and 0.5–5mg of DNA per
milligram of viable tissue. These yields can remain constant over a
decade or more when tissue is stored long-term in vapour-phase
liquid nitrogen freezers, and this is our standard of storage at the
BPC.
INFORMATICS
Informatics (Qualman et al, 2003) can facilitate patient registra-
tion, specimen tracking, tissue cataloguing, quality assurance, and
specimen availability. The ability of databases to organise and
present desired information can also aid in tracking informed
consent and institutional compliance and be used to generate
tissue bank inventory reports to match investigator requests with
specimen availability.
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The components of a system must appear seamless to allow for
efficient data entry, queries and report preparation, and must also
allow for rapid deployment of new services. Consideration should
also be made for the future, as systems will become increasingly
diverse; supporting multiple architectures, platforms, and data-
bases. Exchange of information between different databases at
different institutions may also be or become a concern.
Ideally, an informatics system ensures that data are:
 Available over a long period of time
 Maintained in a standardised format (see common data
elements below)
 Able to be disseminated to others as needed
 Collected from collaborative sources and combined.
Common data elements
The Cancer Cooperative Group Chairs along with the National
Cancer Institute recognised the need for common data elements
across data systems. As a result, the Intergroup Specimen Banking
Committee was formed in 1999 to:
identify existing standards, policies and procedures, particu-
larly those in common usage, which would address the needs of
intergroup banking, rather than invent new ones. The goal was
to deliver a set of recommendations that would require the least
amount of work, change and expense to implement, while
providing sufficient guidance to the research community to
facilitate useful banking efforts in support of correlative
science, to avoid unnecessary conflict and to ensure a sufficient
standard of quality. (Report of the Intergroup Specimen
Banking Committee, 1999)
Rather than establish standards of hardware, operating systems,
or applications, the report instead set forth a standard for
mandatory common data elements. These common elements
provide for such things as uniform reporting, data exchange, and
joint analysis.
Entities subject to these guidelines are medical institutions that
submit specimens to one or multiple tissue banks/repositories,
science review committees, investigators receiving specimens and
responsible for submitting results, and statistical centres (Report
of the Intergroup Specimen Banking Committee, 1999).
Minimum data requirements for banking (Report of the
Intergroup Specimen Banking Committee, 1999)
 All samples and subsamples must have a unique identifier.
 The system must adhere to standard coding mechanism.
 The system must be able to maintain an up-to-date inventory by
unique identifier to include: original and current quantity where
specimens have been sent, when (if) they have been returned,
and when they have been exhausted. The system must also be
able to invalidate samples.
 The database containing information on sample locations
(inventory) may reside at the bank and does not need to be
accessible by systems outside the bank.
 The system must be able to flag (reserve) specimens for a
particular study.
 The system must track the type of informed consent for
research that is allowed.
 The system must track specimens and allow for withdrawal of
consent.
 The system must be able to report and provide query results
across groups to facilitate any combination of a bank per trial, a
bank per disease site, or a bank per group per disease site.
Projects may require samples accrued on more than one trial.
 The system must provide quality control/checks on imported
data.
Centralised inventory system (Qualman et al, 2003)
Inventory is at the heart of tissue bank informatics design
(Figure 1). An inventory module is linked to cataloguing, which
provides for tagging and tracking of such things as informed
consent, group ownership, and tissues reserved or specifically
collected for a protocol or study. This ensures that specimens are
tracked and distributed appropriately and in compliance with the
patient’s informed consent, as well as preventing the total
depletion of a tissue sample.
The system design also streamlines tissue intake and serving of
investigators. Materials are received and processed by a research
assistant and entered directly into the system, while specimen
shipments are processed through the same interface using a
shipment module. The modules keep a precise record of materials
as they are received and shipped to produce a real-time inventory
of what is available. When specimens are received and inventoried
into the central system the specimen is linked back to the specific
cooperative group’s case file. A full history of the specimen from
when it was received to when it was served is maintained per
Biopathology Center System Components
Materials
received
Materials
sent
Inventory
Case
Study
BPCS
Patient
informed
consent
Images Document
imaging
system
Procedure
Surgery
Group
ownership
Comm link
Figure 1 Informatics design of the Biopathology Center System (BPCS).
A centralised inventory system is at the heart of the design, which can
account for both cooperative group and patient-specific data, while
maintaining a real-time inventory of specimen deposits, withdrawals, and
residual tissues. Digital images of clinical documents accompanying
specimens are created and stored using a document imaging system.
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access for reporting purposes.
Virtual private networks
The use of virtual private networking (VPN) has been fundamental
in streamlining the patient enrolment and specimen registration
process, reducing repetitive keying of data and ensuring that
information is synchronised between physically separate sites. This
linking of databases can also be used to create ‘virtual tissue banks’
from the inventory of different sites, thus allowing for optimal
matching of requests and distribution of tissues to reach a larger
market.
The sensitive nature of medical information makes un-
authorised disclosures and data alterations a concern. VPNs can
be a cost-effective solution to provide secure point-to-point
transactions utilising encryption technologies. The primary
requirements for implementation of a secure VPN are:
 Authentication – each end point checks the other and verifies
that the transaction belongs to the secure point-to-point site
before accepting the transaction or request.
 Strong data encryption to protect sensitive information.
 Transaction privacy (public/private key encryption).
 Encryption using a key unique to each information exchange
session.
 Scalability – a VPN needs to be able to grow to accommodate an
increase in connected sites.
 Ability to provide audit information.
 Immediate intrusion/attack detection and response – requires
continuous evaluation of security policies and practices.
ETHICS
Informed consent and confidentiality
Tracking and cataloguing informed consent is the key to banking
informatics. Informed consent is the factor by which all tissues are
qualified or disqualified for use by a potential researcher. The
Intergroup Specimen Banking Committee recently endorsed the
use of a three-item checkbox format for summarising levels of
informed consent (Report of the Intergroup Specimen Banking
Committee, 1999). These levels allow for the patient to designate
whether their tissue or case data may be used for: (i) cancer
research; (ii) general medical research; and (iii) future patient
contact for needed clinical follow-up.
Linkage and coding
Risks posed to subjects from research with their tissues are
strongly related to the identifiability of individual sources of those
tissues (Merz et al, 1997). Data records which can be directly or
indirectly associated with a person’s name or other identifying
information are referred to as linked data. Such identifying
elements are date of birth, treating institution, treating physician,
medical record numbers, social security numbers, etc. The BPCS
uses specialised codes that, by intent, separate the specimen data
from the clinical data to maintain patient anonymity. If there is
patient consent for the data to be linked, the data sets at the BPC
and at a Cooperative Group Statistical Data Center are connected
via a virtual private network (see section entitled Virtual Private
Networks) and decoding can occur.
To permanently de-link data, any codes that will link or identify
data or tissues with the donor must be removed, such that even the
database manager can no longer trace a tissue or its related data
back to the donor.
Investigator feedback
One metric used to assess the effectiveness of a banking operation
is defining ‘who is served and how well’. These questions are
answered using an investigator feedback questionnaire process
which is performed annually. Despite its apparent success, the
CHTN has found through its investigator surveys that not all
investigators have received the number of specimens that they
desired. In a composite survey of 554 investigators (43% response
rate) carried out in 2000 by the CHTN, the following queries with
responses were obtained (Table 1).
A substantial minority of CHTN investigators, slightly more
than one-quarter of them, did not receive the number of specimens
they expected. Some of these investigators have unrealistic
expectations as to what specimens are available. The dilemma of
the CHTN is how to draw the line between their obligation to
facilitate research and the risk of frustrating investigators by
overestimating which types of specimens can be obtained for their
research. ‘Difficult-to-serve’ projects generally have inherent
limitations which fall into the following categories:
1. Limitation on amount of tissue available.
2. Limitation based on tissue rarity.
3. Limitation on timing of tissue procurement.
4. Limitation based on tissue consent.
Limitation based on amount of tissue available This is probably
the single biggest challenge the CHTN faces in meeting investigator
needs. Investigators often ask for multiple aliquots (0.5–1g) of any
given tumour type when those amounts are not realistically
available clinically. Advances in screening techniques have led to
detection of tumours (e.g. breast cancer) in earlier stages when
tumours are generally smaller. Shifts in therapy are leading to
fewer surgical resections of certain tumours (e.g. radiation therapy
of prostate cancer and chemotherapy/radiation therapy for small
cell carcinoma of lung). Bulky end-stage tumours are often not
resected, and rapid autopsy (less than 1h) is rare, such that post-
mortem tissues may be less than adequate in quality. Some
specimens (e.g. cervical cone biopsies, primary melanoma exci-
sions) may be totally submitted to document minute foci of
tumour or depth of invasion. Tissue requests should be for the
smallest possible sample size, since the CHTN supplies those
before considering large size requests. The largest pool of breast or
prostate surgical specimens, for example, are available in aliquots
of 0.1–0.25g or less.
Table 1 Responses to a written survey from investigators who have
used CHTN tissues
Responses (%)
Query
Excellent
or good
Okay or
less
Responsiveness and helpfulness of CHTN staff 94 6
Completeness and accuracy of standard data
provided with the specimens (site, tissue type[s],
diagnosis)
94 6
How well did the size or weight of specimens
received correlate with request as approved by
CHTN?
89 11
Was tissue prepared according to specifications as
agreed upon with the CHTN?
92 8
Overall quality of tissue received 90 10
Satisfaction with number of specimens received,
based upon feedback given by CHTN
74 26
Overall satisfaction with CHTN services 89 11
Importance of the availability of the CHTN tissue to
your research
93 7
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human tissue bank per se, but rather a source of targeted
prospective human tissue collection based on investigator need.
Limited banking is used to meet specific requests, and rare
specimens are banked for longer periods. These are precisely the
reasons why the BPC developed banking mechanisms for its
cooperative group affiliations.
Limitations based on timing of tissue procurement The issue of
time post-surgery can also affect the number of specimens served
to an investigator. While the CHTN regularly serves researchers
who require rapidly frozen tissue for mRNA preparation,
investigator requests for shorter time intervals (e.g. less than
20min) significantly limit the number of potentially available
specimens. Patient diagnosis is the first concern of the CHTN and
diagnostic specimens are processed before research specimens.
Most surgical specimens are available within 2h of excision and
many within 1h post-excision. Requesting time intervals under
30min will seriously limit the number of potential specimens.
Also, there is increasing evidence that at least ribosomal RNA is
not rapidly degraded following removal of surgical tissues from the
human body (Jewell et al, 2002). Similarly, it is unusual to see post-
mortem intervals of less than 8–12h; a 3–4h post-mortem
interval is occasionally achieved, but post-mortem intervals which
are more rapid can only be achieved by focused specific autopsy
protocols facilitated by the clinician.
Limitations of tissue availability based on consent Only tissues
that would otherwise be discarded are taken from surgical
specimens. Tissues sampled at autopsy must also be within the
scope of the signed consent form. Consequently, most ‘normal’
tissues are available from surgical resections to remove diseased
and normal adjacent tissue or due to trauma (which are rare).
Specific regions of the body will seldom have large areas of ‘normal
tissue’ resected surgically (e.g. specific areas of the brain);
accordingly, greater quantities of such tissues are more likely to
be obtained from autopsy. Ethical problems arise when there is
appreciable risk of biopsy for research purposes alone, and costs of
research-specific surgical or medical procedures are usually
prohibitive. The CHTN is not involved in obtaining tissue removed
solely for research purposes; where this is an expectation in a
cooperative group study, specific informed consent must be
obtained.
It is encouraging to note that overall investigator satisfaction
with CHTN services is in the range of 90%. This is because the
CHTN is not just a supplier of tissues, but is also an educator on
how investigators can increase their project’s success, which may
include referring the investigator to other tissue resources. When
an investigator makes an unrealistic or unreasonable request, a
letter is sent to the investigator explaining the problem with their
request. The CHTN provides information on alternative technol-
ogies or methods (e.g. surgery vs autopsy) to serve the request. For
rare requests, the CHTN institution serving as primary contact for
the investigator informs the investigator in the acceptance letter
that the specimens are rare, and estimates how long it might take
to fill the request. These requests are also referred immediately to
the National Cancer Institute’s tissue expediter (301-496-7147 or
tissexp@mail.nih.gov) so as to assist the investigator in finding
new/other tissue resources.
FUTURE CHALLENGES
The ultimate role of the pathologist as a tumour banker in this
setting is that of both a data miner and tissue refiner (Becich,
2000). One of the chief complaints of investigators concerning
tumour banks is the lack of sizeable specimens received for their
research. It is incumbent upon the pathologists/bankers, as they
review a research proposal, to educate the investigator both on the
inherent limitations of tissue acquisition and alternate research
techniques that utilise less tissue. Fortunately, with the advent and
increased usage of nucleic acid amplification techniques and
fluorescent in situ hybridisation, such alternate techniques are
more readily available; moreover, coincidental use of microarray
technologies with nucleic acid amplifications may allow for
screening of thousands of genes (Farkas et al, 1996). Ultimately,
more can be done with less, with careful planning and commu-
nication.
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